20537 ⎘
Medicinal preparations containing organic active ingredients; Carbohydrates; Sugars; Derivatives thereof; Compounds having three or more nucleosides or nucleotides Double-stranded nucleic acids or oligonucleotides
Methods and products for nucleic acid production and delivery
#2402ENHANCED CANCER TREATMENT AND MONITORING USING RECOMBINANT VECTORS
#2403Methods for treating hair loss disorders
#2404Methods and compositions for unsilencing imprinted genes
#2405Compositions and methods for silencing hepatitis B virus gene expression
#2406Treatment of facioscapulohumeral dystrophy
#2407EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#2408Formulations for the delivery of active ingredients
#2409METHOD FOR PREVENTION OF COLECTOMY
#2410CFTR MRNA compositions and related methods and uses
#2411THE PROTEIN KINASE ACTIVITY OF PHOSPHOGLYCERATE KINASE 1 AS A TARGET FOR CANCER TREATMENT AND DIAGNOSIS
#2412Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer
#2413NOVEL DIAGNOSTIC AND THERAPEUTIC TARGET IN INFLAMMATORY AND/OR CARDIOVASCULAR DISEASES
#2414Fluorogenic probes and their use in quantitative detection of target RNA sequences
#2415Agents for improved delivery of nucleic acids to eukaryotic cells
#2416Compositions and methods thereof for down-regulation of genes following oral delivery of an RNAi molecule bioencapsulated within plant cells
#2417METHODS AND COMPOSITIONS FOR TREATING MALIGNANT TUMORS ASSOCIATED WITH KRAS MUTATION
#2418Compositions and methods for reactivating latent immunodeficiency virus
#2419COMPOSITIONS AND METHODS
#2420Sequence Specific and Organism Specific Antimicrobials and Related Materials and Methods
#2421Inflammatory disease diagnosis and methods of treatment using down-regulators of lipopolysaccharide-responsive beige-like anchor
#2422MICRONEEDLE ARRAYS FOR ACTIVE AGENT DELIVERY
#2423Macrophages eat cancer cells using their own calreticulin as a guide
#2424Combination tumor immunotherapy
#2425METHODS OF TREATING UROTHELIAL CARCINOMA
#2426Method for identification of anti-HIV human miRNA mimics and miRNA inhibitors and anti-HIV pharmaceutical compounds
#2427Inhibin as targetable regulators of angiogenesis
#2428EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#2429RAAV-BASED COMPOSITIONS AND METHODS FOR TREATING ALPHA-1 ANTI-TRYPSIN DEFICIENCIES
#2430Method for modifying T cell population
#2431Amphiphilic polymer systems
#2432Co-activation of mTOR and STAT3 pathways to promote neuronal survival and regeneration
#2433TMPRSS6 iRNA compositions and methods of use thereof
#2434USE OF RAD18 INHIBITORS IN THE TREATMENT OF TUMORS
#2435PHARMACEUTICAL COMPOSITIONS COMPRISING MICRORNA
#2436Modulation and detection of a neuronal alternative splicing regulatory network for treatment and diagnosis of neurological disorders
#2437Treatment and prevention of thrombosis using an anti-miR
#2438Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
#2439Methods and compositions for treating autoimmune disorders by targeting Kv1.3 ion channels with functionalized lipid-derived nanovesicles
#2440METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS
#2441Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
#2442Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#2443Modulation of alternative MDM2 splicing
#2444RNAI induced huntingtin gene suppression
#2445Mitochondrial phosphate carrier targets for treating soft-tissue calcification
#2446Oligonucleotide having non-natural nucleotide at 5′-terminal thereof
#2447CNS targeting AAV vectors and methods of use thereof
#2448Methods and Compositions for Selecting siRNA of Improved Functionality
#2449siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)
#2450Hepatitis D virus (HDV) iRNA compositions and methods of use thereof
#2451Hepatitis B virus (HBV) iRNA compositions and methods of use thereof
#2452Combination therapies for inner ear sensory hair cell regeneration/replacement
#2453Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications
#2454ENCAPSULATION OF MESSENGER RNA
#2455Methods for the prevention and the treatment of extracapillary glomerulonephritis
#2456Methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections
#2457Cell penetrating stapled peptide, manufacturing method therefor, and use thereof
#2458Nucleic acid complexes
#2459Polymalic acid-based nanobiopolymer compositions
#2460METASTASIS SPECIFIC SPLICE VARIANTS OF MENA AND USES THEREOF IN DIAGNOSIS, PROGNOSIS AND TREATMENT OF TUMORS
#2461Preventing and treating inflammatory skin diseases
#2462Methods and compositions for preventing ischemia reperfusion injury in organs
#2463Compounds and methods for the modulation of COMP
#2464Methods for modulating ATRX-dependent gene repression
#2465Methods For Using Nucleic Acid Aptamers For Directed Templated Assembly
#2466Bruton's tyrosine kinase as anti-cancer drug target
#2467Cationic lipid
#2468TLR9 TARGETED CYTOTOXIC AGENTS
#2469Methods for treating and/or limiting development of diabetes
#2470Methods of treating impaired wound healing
#2471CORE-SHELL PARTICLE FORMULATION FOR DELIVERING MULTIPLE THERAPEUTIC AGENTS
#2472Polymers and polymeric nanogels with hydrophilics encapsulation and release capabilities and methods thereof
#2473Combination method for treating cancer by targeting immunoglobulin superfamily member 1 (IGSF1) and mesenchymal-epithelial transition factor (MET)
#2474Organic compositions to treat Beta-ENaC-related diseases
#2475PH-sensitive peptides and their nanoparticles for drug delivery
#2476Biotin complexes for treatment and diagnosis of Alzheimer'S disease
#2477Oligonucleotide compositions with enhanced efficiency
#2478Modulation of AGPAT5 expression
#2479Albumin production and cell proliferation
#2480Compositions and methods for inhibiting expression of transthyretin
#2481METHODS FOR DIAGNOSING AND TREATING CD1D RESTRICTED GAMMA/DELTA T CELL LYMPHOMAS
#2482Compositions and methods for modifying a predetermined target nucleic acid sequence
#2483METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS
#2484Means and methods for treatment of early-onset Parkinson's disease
#2485INCREASING ATOH1 LIFE TO DRIVE SENSORINEURAL HAIR CELL DIFFERENTIANTION
#2486Direct and selective inhibition of MDM4 for treatment of cancer
#2487Matriptase inhibitors and uses thereof against orthomyxoviridae infections
#2488MicroRNA-200 based approaches for modulating bone formation inhibition and bone regeneration
#2489SELF-ASSEMBLED NANOSTRUCTURES
#2490Delivery of small interfering RNA and micro RNA through nanogels containing hydrophobic pseudo-peptides
#2491Pharmaceutical composition for treatment of cancer comprising RNA oligonucleotide
#2492Hippo and dystrophin complex signaling in cardiomyocyte renewal
#2493Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides
#2494Antisense antiviral compounds and methods for treating a filovirus infection
#2495PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION AND TREATMENT, CONTAINING NDRG3 EXPRESSION OR ACTIVITY INHIBITOR AS ACTIVE INGREDIENT, OR NDRG3 PROTEIN-SPECIFIC ANTIBODY AND USE THEREOF
#2496NOVEL TGF-ALPHA MUTANT PROTEINS
#2497Method for preparing a magnetic chain structure
#2498METHODS AND COMPOSITIONS FOR INHALATION DELIVERY OF CONJUGATED OLIGONUCLEOTIDE
#2499Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression
#2500Treatment of hormonal disorders of growth
#2501POLYMER CONJUGATES OF BOX-A OF HMGB1 AND BOX-A VARIANTS OF HMGB1
#2502MicroRNA (miRNA) and downstream targets for diagnostic and therapeutic purposes
#2503Extended-release drug delivery compositions
#2504Amphiphile-polymer particles
#2505Gene carrier using cell-derived nanovesicles and method for preparing the same
#2506ANTI-TUMOR THERAPY
#2507LATS AND BREAST CANCER
#2508Organic compositions to treat HSF1-related diseases
#2509Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
#2510Methods and materials for modulating resistance to apoptosis using KLK6 antisense and MIRNA molecules
#2511Method for assessing the efficacy of IMiDs and composition or combination for use in treating IMiD sensitive diseases
#2512Compositions and methods for dengue virus chimeric constructs in vaccines
#2513Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
#2514Compositions and methods for diagnosis and treatment of prostate cancer
#2515RNA interference compositions targeting heat shock protein 90 and methods of use thereof
#2516Therapeutic compositions
#2517Compositions and methods for treating and preventing inflammation
#2518NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
#2519Methods for treating and/or limiting development of diabetes in subjects with amyotrophic lateral sclerosis
#2520Method for treatment of inflammatory skin disorders with inhibitors of IL-36 proteolytic processing
#2521Polycarbonates bearing aromatic N-heterocycles for drug delivery
#2522Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
#2523Cancer treatment and immune system regulation through FAT10 pathway inhibition
#2524Compositions and methods for treating vascular disorders
#2525Methods of preserving and protecting pancreatic beta cells and treating or preventing diabetes by inhibiting NOX-1
#2526Lipids and lipid compositions for the delivery of active agents
#2527COMBINING ANTI-HLA-DR OR ANTI-TROP-2 ANTIBODIES WITH MICROTUBULE INHIBITORS, PARP INHIBITORS, BRUTON KINASE INHIBITORS OR PHOSPHOINOSITIDE 3-KINASE INHIBITORS SIGNIFICANTLY IMPROVES THERAPEUTIC OUTCOME IN CANCER
#2528Compositions and Methods for Increasing Red Blood Cells
#2529Triggering RNA interference with RNA-DNA and DNA-RNA nanoparticles
#2530Stable formulations of lipids and liposomes
#2531Methods and pharmaceutical compositions for treatment of cystic fibrosis
#2532COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#2533MODULATION OF APOLIPOPROTEIN CIII (APOCIII) EXPRESSION
#2534Particles comprising single stranded RNA and double stranded RNA for immunomodulation
#2535Compositions for modulating cancer stem cells and uses therefor
#2536Lipid vesicle compositions and methods of use
#2537Methods of detecting DDR2 mutations
#2538MUCOSAL HEALING PROMOTER
#2539Repressor on IFN-λ promoter and siRNA against GATA1, EVI1, and CRX to alter IFN-λ gene activity
#2540Delivery of dsRNA to arthropods
#2541Methods of treating, inhibiting and/or preventing an auditory impairment
#2542Agent for preventing or treating demyelinating disease
#2543Bacterially derived intact minicells that encompass plasmid free DNA and methods of using the same
#2544Targeting ligands for therapeutic compounds
#2545COMPLEMENT COMPONENT C5 IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#2546ANTI-CANCER AGENT SENSITIVITY-DETERMINING MARKER
#2547CDC25A inhibitor for the treatment of drug resistant cancer or for the prevention of tumor relapse
#2548NUCLEIC ACID CAPABLE OF INHIBITING EXPRESSION OF BETA-2GPI
#2549Interfering RNA molecules
#2550Nanoparticles for Use in Medical and Research Applications
#2551METHODS TO UPREGULATE AND SUPPRESS AN EXPRESSION OF IMMUNOMODULATORY CELLS
#2552Methods and Pharmaceutical Compositions for Treating Lymphoid Malignancy
#2553Use of CDK9 inhibitors to reduce cartilage degradation
#2554Cell-free methods of producing vault particles and vault particles resulting therefrom
#2555NUCLEIC ACIDS, AND USES THEROF
#2556Antiviral agent comprising RNA oligonucleotide
#2557Inhibitory Oligonucleotides for Treating Tumors
#2558Lipid nanoparticle compositions and methods for MRNA delivery
#2559Micellic assemblies
#2560Small molecule inhibitors of RNA binding motif (RBM) proteins for the treatment of acute cellular injury
#2561Compositions and methods for modifying a predetermined target nucleic acid sequence
#2562Compositions for controlling mites in bees
#2563Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAS targeting the expanded hexanucleotide repeat
#2564DETECTION OF VIRAL INFECTION
#2565PME-1 as a biomarker to predict and diagnose an increased risk of endometrial cancer and gene silencing of PME-1 to inhibit epithelial to mesenchymal transition
#2566COMPOSITIONS AND METHODS FOR TREATING CANCER
#2567RNA aptamers against transferrin receptor (TFR)
#2568APTAMERS FOR BINDING FLAVIVIRUS PROTEINS
#2569Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
#2570Functionalized phosphorodiamites for therapeutic oligonucleotide synthesis
#2571Cationic lipid
#2572Oil-in-water emulsions that contain nucleic acids
#2573Treatment of angiogenesis-associated diseases using RNA complexes that target ANGPT2 and PDGFB
#2574Antagonistic PD-1 aptamer and its applications in cancer therapy related applications
#2575CXCR4 INHIBITING CARRIERS FOR NUCLEIC ACID DELIVERY
#2576DELIVERY MOLECULES FOR THERAPEUTICS
#2577MiRNA-489 in treatment of breast cancer
#2578Methods and compositions for inhibiting growth and epithelial to mesenchymal transition (EMT) in cancer cells
#2579Prophylactic agent and therapeutic agent for fibrodysplasia ossificans progressiva
#2580Antagonistic CTLA-4 aptamers and applications thereof in enhancing immune activity
#2581Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
#2582MrgprX2/MrgprB2 expressing cell based assay to detect pseudo-allergic drug reactions and to identify blockers to prevent the adverse reactions
#2583dsRNA for treating viral infection
#2584Compositions for Targeted Delivery of siRNA
#2585Method for Preventing or Treating a Protein Aggregation Disease
#2586Methods of inhibiting cancer stem cells with HMGA1 inhibitors
#2587METHODS OF GLUCOCORTICOID THERAPY AND DETERMINING RESPONSIVENESS THEREOF
#2588Preventive or therapeutic agent for fibrosis
#2589ANTI-INFLAMMATORY TREATMENT VIA INHIBITION OF ENDOTHELIAL CELL KINESIN LIGHT CHAIN 1, VARIANT 1 (KLC1C)
#2590Diagnostic and therapeutic tool for cancer
#2591Compositions And Methods For Treating Tumors And Immune Based Inflammatory Diseases
#2592Cationic lipid
#2593Method of encapsulating a nucleic acid in a lipid nanoparticle host
#2594PERFORIN 2 DEFENSE AGAINST INVASIVE AND MULTIDRUG RESISTANT PATHOGENS
#2595Dual molecular delivery of oligonucleotides and peptide containing conjugates
#2596Methods for treating insulin resistance and for sensitizing patients to GLP1 agonist therapy
#2597Bruton's tyrosine kinase as anti-cancer drug target
#2598Compositions and methods for modifying a predetermined target nucleic acid sequence
#2599Compositions and methods for modulating NCOA4-mediated autophagic targeting of ferritin
#2600Inhibition of Bruton's tyrosine kinase (Btk) in the lung to treat severe lung inflammation and lung injury
#2601Method for treating fibrosis using siRNA and a retinoid-lipid drug carrier
#2602Cross-linked polymer modified nanoparticles
#2603Combination therapy of acellular pro-tolerogenic and pro-inflammatory preparations for modulating the immune system
#2604Drug delivery particle and method for producing the same
#2605Liposomes with ginsenoside as membrane material and preparations and use thereof
#2606METHOD FOR OPENING TIGHT JUNCTIONS
#2607Treatment of Liver Cancer through Embolization Depot Delivery of BORIS Gene Silencing Agents
#2608APTAMERS FOR TOPICAL DELIVERY
#2609Methods for the treatment of cardiovascular fibrosis
#2610Methods and compositions for treating malignant tumors associated with kras mutation
#2611Methods and compositions for treating a Serpinc1-associated disorder
#2612Reducing nonsense-mediated mRNA decay
#2613Treatment of amyotrophic lateral sclerosis
#2614Method of producing lipid nanoparticles for drug delivery
#2615Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
#2616Modulation of BCL11A for treatment of hemoglobinopathies
#2617Nanoparticle type oligonucleotide structure having high efficiency and method for preparing same
#2618LIPID PARTICLES WITH CATIONIC LIPIDS FOR RNA DELIVERY
#2619NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF
#2620Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics
#2621Combination of Anti-Clusterin Oligonucleotide with HSP90 Inhibitor for the Treatment of Prostate Cancer
#2622IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
#2623Transferrin/transferrin receptor-mediated siRNA delivery
#2624System utilizing light-activated ion channel protein (VChR1) for optical stimulation of target cells
#2625LIPID FORMULATION
#2626Apoptosis inducer
#2627Organic compositions to treat APOC3-related diseases
#2628Amine cationic lipids and uses thereof
#2629Pharmaceutical composition and uses thereof
#2630Diester and triester based low molecular weight, biodegradeable cationic lipids for oligonucleotide delivery
#2631Inhibition of chemokine CCL7 or receptor CCR3 of same for the treatment and diagnosis of prostate cancer
#2632CO-ACTIVATION OF MTOR AND STAT3 PATHWAYS TO PROMOTE NEURONAL SURVIVAL AND REGENERATION
#2633METHOD OF TREATING HYPERLIPIDEMIA AND ATHEROSCLEROSIS WITH MIR-30C
#2634Multifunctional RNA nanoparticles and methods of use
#2635Inhibitors of metastasis
#2636Peptide, complex of peptide and siRNA and use thereof
#2637Ph-sensitive and bioreducible polymer-virus complex for cancer treatment
#2638Disintegratable core/shell silica particles for encapsulating and releasing bioactive macromolecules
#2639Nanoparticle-stabilized nanocapsules and methods of preparation and use for nucleic acid delivery
#2640Devices and methods for treatment of ocular disorders through delivery of therapeutic nucleic acids
#2641Method for treating kidney disease with a SLIT2-binding extracellular domain of ROBO2
#2642Serpina1 iRNA compositions and methods of use thereof
#2643Delivery of hydrophobic active agent particles
#2644PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY
#2645PLASMA MEMBRANE VESICLES COMPRISING FUNCTIONAL TRANSMEMBRANE PROTEINS
#2646CELL DELIVERY SYSTEM AND METHOD
#2647Monomers and oligonucleotides comprising cycloaddition adduct(s)
#2648RNAi PHARMACEUTICAL COMPOSITION FOR SUPPRESSING EXPRESSION OF CKAP5 GENE
#2649Peptide ligands for hepatic stellate cells
#2650Compounds and methods for trans-membrane delivery of molecules
#2651Lipocationic polymers and uses thereof
#2652Diblock copolymers and polynucleotide complexes thereof for delivery into cells
#2653Method for stabilization and delivery of therapeutic molecules
#2654Compositions and methods for controlling arthropod parasite and pest infestations
#2655Methods for enhancing or decreasing the levels of MIR124 and MIR29 in subjects with muscular dystrophy
#2656MicroRNA composition for the treatment of neuroblastoma
#2657Dock-and-Lock (DNL) Complexes for Therapeutic and Diagnostic Use
#2658METHODS FOR TREATING AND PREVENTING ALLERGIES AND ACUTE ALLERGIC RESPONSES
#2659Nanostructures for modulating intercellular communication and uses thereof
#2660Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites
#2661Methods for improving cognitive function via modulation of quinone reductase 2
#2662METHODS AND COMPOSITIONS FOR PREVENTING ISCHEMIA REPERFUSION INJURY IN ORGANS
#2663Retinoid-lipid drug carrier
#2664Cell penetrating peptides for intracellular delivery of molecules
#2665Near-infrared light-activated proteins
#2666Carrier nanoparticles and related compositions, methods and systems
#2667COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES
#2668Compositions and methods for modified dendrimer nanoparticle delivery
#2669Compositions and methods for prognosis of ovarian cancer
#2670Individualized cancer therapy
#2671Modulation of TMPRSS6 expression
#2672RNAi-Mediated Inhibition of Frizzled Related Protein-1 for Treatment of Glaucoma
#2673Treatment of Collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
#2674Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Cell Types
#2675Organic compositions to treat HSF1-related diseases
#2676COMPOSITIONS AND METHODS FOR ANTI-LYST IMMUNOMODULATION
#2677Methods for treating occular irritation involving tearing by administering modulators of TRPM8
#2678Use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma
#2679Compositions and methods for inhibiting expression of CD274/PD-L1 gene
#2680Targeting microRNAs for metabolic disorders
#2681MicroRNAs 206 and 21 cooperate to promote RAS-extracellular signal-regulated kinase signaling by suppressing the translation of RASA1 and SPRED1
#2682Antisense nucleic acids
#2683Esophageal cancer marker and use thereof
#2684Metal-particle-based oral-administrating liver-specific nucleic acid delivery system and method of manufacturing the same
#2685SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions
#2686Compositions and methods for transport across the blood brain barrier
#2687Therapeutic compositions comprising n-alkyl-hydroxy polymers
#2688Peptide-Based In Vivo siRNA Delivery System
#2689Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
#2690MICRO/NANO COMPOSITE DRUG DELIVERY FORMULATIONS AND USES THEREOF
#2691Compositions and methods for promoting skin regeneration and hair growth
#2692Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA
#2693Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway
#2694Therapeutic drug for malignant tumors
#2695Anti-NGF antibodies that selectively inhibit the association of NGF with TRKA without affecting the association of NGF with P75
#2696MULTIBLOCK COPOLYMERS
#2697Pharmaceutical combination comprising a CIP2A silencing agent for use in the treatment of a hyperproliferative disorder, preferably one with impaired P53 function
#2698Targeting PARP1 for treatment of TSC and cancers
#2699Method for treating vaginal dryness by administering transient receptor potential cation channel subfamily M member 8 (TRPM8) receptor agonists
#2700THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME